Open Access Open Access  Restricted Access Subscription or Fee Access

Helicobacter pylori mediated Gastritis, Peptic Ulcer and Gastric Cancer

D G Naik

Abstract


It is established that Helicobacter pylori infection is a major cause of gastritis, duodenal ulcer, stomach cancer, and also causes gastric mucosa-associated lymphoid tissue lymphoma. Now, H. pylori infection is considered to be one of the major public health issues in developing countries. At least 50% of world population are infected with H. pylori especially in developing countries. The prevalence of H. pylori is highly variable in relation to geography, age, and socio-economic factors. The causative agent is a Gram negative microaerophile and motile with multiple polar flagella. The main mode of transmission is through person to person contact via fecal-oral and Oral-Oral route. Lack of personal hygiene, poor sanitation and overcrowding facilitates transmission of the organism. The organisms have been isolated from treated water sources. Infection is usually acquired in childhood and often goes unnoticed. The organism has different mechanisms to escape from natural innate immunity and produce powerful cytotoxins that are associated with gastric cancer. Cytotoxin associated gene A is present in more than 90 % of the strains in developing countries. The cytotoxins and released interlukins upgrade the mucosal inflammation. The main risk factors include smoking, consumption of alcohol, and non-steroidal anti-Inflammatory drugs. The progressive stages described include normal stomach mucosa lining, chronic gastritis, atrophic gastritis, intestinal metaplasia, dysplasia, and stomach cancer. In laboratory diagnosis various tests employed are histological assessment, culture, urease based test, fecal antigen test and serological tests. The polymerase chain reaction is also used to detect the organisms. High resistance to commonly used antibiotics are reported by many studies. In the absence of vaccine, it is important to study the prevalence rate of H. pylori, the genotypes, biomarkers, and antimicrobial resistance pattern, effective treatment and eradication. In addition, morbidity and mortality can be reduced by early detection, diagnosis, and effective treatment.

Full Text:

PDF

References


http://www.cancerresearchuk.org/cancer-info/cancerstats/

Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13(6): 607–15p.

http://www.cancer.org/cancer/stomachcancer/detailedguide/stomach-cancer-

key-statistics.

http://www.cdc.gov/ulcer/files/hpfacts.pdf

Dent JC, McNulty CAM. Evaluation of a new selective medium for Campylobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 1988, 7: 555–68p.

Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: A combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49(3): 347–53p.

http://www.worldgastroenterology.org/helicobacter-pylori-in-developing-countries.html

Al-Sulami AA, Al-Taee AMR, Juma’a MG. Isolation and identification of Helicobacter pylori from drinking water in Basra governorate. Iraq East Mediterr Health J. 2010; 16(9): 920–5p.

http://www.merckmanuals.com/professional/gastrointestinal_disorders/gastritis_and_peptic_ulcer_disease/helicobacter_pylori_infection.html

Atherton JC. The pathogenesis of Helicobacter pylori-induced gastro-duodenal diseases. Annual Review of Pathology. 2006; 1:63–96p.

Kusters JG. van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clinical Microbiology Reviews. 2006; 19(3): 449–90p.

Rafeey M, Ghotaslou R, Milani M, et al. Association between Helicobacter pylori, cagA, and vacA Status and Clinical Presentation in Iranian Children. Iran J Pediatr. 2013; 23(5): 551–56p.

Hosseini E, Poursina F, de Wiele TV, et al. Helicobacter pylori in Iran: A systematic review on the association of genotypes and gastroduodenal diseases. J Res Med Sci. 2012; 17(3): 280–92p.

Contreras M, Abrante L, Salazar V, et al. Heterogeneity of cag genotypes of Helicobacter pylori in the esophageal mucosa of dyspeptic patients and its relation to histopathological outcomes. Int J Infect Dis. 2014; 26: 91–5p.

1Memon AA, Hussein NR, Miendje Deyi VY, et al. Vacuolating cytotoxin genotypes are strong markers of gastric cancer and duodenal ulcer-associated Helicobacter pylori strains: a matched case-control study. J Clin Microbiol. 2014; 52(8): 2984–9p.

Pereira W. N, Ferraz MA, Zabaglia L. M. et al. Association among H. pylori virulence markers dupA, cagA and vacA in Brazilian patients. J Venom Anim Toxins Incl Trop Dis. 2014; 20(1): 1p.

Wang M. Y, Chen C, Gao X. Z, et al. Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in a region at high risk of gastric cancer. Microb Pathog. 2013; 59–60:13–8p.

Karabiber H, Selimoglu M.A, Otlu B, et al. Virulence factors and antibiotic resistance in children with Helicobacter pylori gastritis. J Pediatr Gastroenterol Nutr. 2014; 58(5): 608–12p.

Johannes G.K, van Vliet Arnoud H. M., Ernst J. K.Pathogenesis of Helicobacter pylori Infection Clin Microbiol Rev. 2006 Jul; 19(3): 449–90p.

Pandya HB, Patel JS, Agravat HH, et al.Noninvasive Diagnosis of Helicobacter pylori: Evaluation of Two Enzyme Immunoassays, Testing Serum IgG and IgA Response in the Anand District of Central Gujarat,India. J Clin Diagn Res. 2014; 8(6): DC12–5p.

Rasheed F, Khalid A, Saadia A, et al. Correlation of 13C urea breath test values with Helicobacter pylori load among positive patients. Hepatogastroenterology. 2014 Jan-Feb; 61(129):125–8p.

Patel SK, Pratap CB, Jain AK, et al. Diagnosis of Helicobacter pylori: what should be the gold standard? World J Gastroenterol. 2014; 20(36): 12847–59p.

http://www.mayoclinic.org/diseases-conditions/h-pylori/basics/treatment/con-20028643.

Song Z, Zhang J, He L, et al. Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients. Dig Liver Dis. 2014; 46(12): 1077–81.

Yang T, Li H, Chen J, et al. Epidemiological study on antibiotic resistance among Helicobacter pylori in Taizhou district, Zhejiang, 2010–2013. Zhonghua Liu Xing Bing Xue Za Zhi. 2014; 35(6): 704–7p.

Karczewska E, Klesiewicz K, Wojtas-Bonior I, et al. Levofloxacin resistance of Helicobacter pylori strains isolated from patients in southern Poland, between 2006–2012. Acta Pol Pharm. 2014; 71(3): 477–83p.

Boyanova L, Davidkov L, Gergova G, et al. Helicobacter pylori susceptibility to fosfomycin, rifampin, and 5 usual antibiotics for H. pylori eradication. Diagn Microbiol Infect Dis. 2014; 79(3): 358–61p.




DOI: https://doi.org/10.37628/ijbb.v1i1-2.19

Refbacks

  • There are currently no refbacks.